DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291

DYRK1A is considered a potential cancer therapeutic target, but the role of DYRK1A in NSCLC oncogenesis and treatment requires further investigation. In our study, high DYRK1A expression was observed in tumour samples from patients with lung cancer compared with normal lung tissues, and the high lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yang‐ling, Ding, Ke, Hu, Xiu, Wu, Lin‐wen, Zhou, Dong‐mei, Rao, Ming‐jun, Lin, Neng‐ming, Zhang, Chong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815810/
https://www.ncbi.nlm.nih.gov/pubmed/31454149
http://dx.doi.org/10.1111/jcmm.14609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815810/
https://www.ncbi.nlm.nih.gov/pubmed/31454149
http://dx.doi.org/10.1111/jcmm.14609

Ejemplares similares